Ampersand Health has launched a digital therapy to enable people living with inflammatory arthritis to self-manage their condition.
My Arthritis DTx can support people with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Via the app, they can obtain educational resources and courses independently or in conjunction with a clinical team if their NHS Trust uses the platform.
The therapy is underpinned by behavioural science, using techniques from cognitive behavioural therapy, acceptance and commitment therapy, and mindfulness.
It is designed to improve patients’ mental health and quality of life by helping address their general wellbeing, adherence to medication and ability to cope with their symptoms with additional content in development.
Clinical trials are currently underway for My Arthritis, which has been developed by Ampersand Health in collaboration with leading specialists across the UK including experts from King’s College Hospital, University Hospitals Dorset (UHD) and the National Rheumatoid Arthritis Society.
My Arthritis is being implemented at UHD to improve care and efficiency for its patients.
‘We know that patients who are engaged in their own care and have a strong understanding of their condition will feel more empowered and in control of their condition, and this increases their chances of better health outcomes,’ said Dr Jonathan Marks, consultant rheumatologist at UHD.
‘We learned during Covid-19 how out of date our traditional communication with patients is, this app will enable us to build better channels and processes for communication that can revolutionise the outpatient experience for both patients and clinical teams, bringing our communication into the 21st century.’
Founded in 2018 and backed by private equity company Crista Galli Ventures, Ampersand develops interventions that improve the quality of life and mental wellbeing of people with inflammatory conditions such as Crohn’s, ulcerative colitis, arthritis and psoriasis.